Pharmacokinetic drug interactions of asciminib with the sensitive cytochrome P450 probe substrates midazolam, warfarin, and repaglinide in healthy participants

Asciminib, a first‐in‐class BCR‐ABL1 inhibitor that works by Specifically Targeting the ABL Myristoyl Pocket (STAMP), is a new treatment option for patients with chronic myeloid leukemia who no longer benefit from currently approved tyrosine kinase inhibitors. In vitro, asciminib reversibly inhibits...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoch, Matthias, Sengupta, Tirtha, Hourcade‐Potelleret, Florence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9199882/
https://www.ncbi.nlm.nih.gov/pubmed/35293131
http://dx.doi.org/10.1111/cts.13252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9199882/
https://www.ncbi.nlm.nih.gov/pubmed/35293131
http://dx.doi.org/10.1111/cts.13252

Ejemplares similares